Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a phase I study of second primary tumor prevention in early stage (stage I/II)
patients diagnosed with squamous cell carcinoma of the head and neck (SCCHN).